| Baseline characteristics and measurements | ARTEMIS-IPF | GAP cohort | |
| No serum | Serum | ||
| Subjects | 423 | 69 | 104 |
| Age years | 65.9±7.3 | 66.2±7.0 | 66.7±8.9 |
| Males | 303 (72) | 52 (75) | 73 (70) |
| FVC % predicted | 69.0±13.5 | 69.8±12.1 | 66.1±17.7# |
| DLCO % predicted | 43.4±14.1 | 42.1±11.1 | 47.8±18.0# |
| 6MWD m | 416.2±120.1 | 398.6±115.8 | NA |
| PAP mmHg | 20.4±7.1 | 20.4±5.9 | NA |
| CPI score | 52.2±10.8 | 52.5±8.9 | 51.0±13.0 |
| SGRQ score | 39.4±19.5 | 38.0±18.4 | NA |
| TDI score | 7.3±2.4 | 7.5±2.4 | NA |
| Follow-up days median±sd | 237±143 | 245±177 | 455±340 |
| Deaths | 23 (5) | 9 (13) | 43 (41)¶ |
Data are presented as n, mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWD: 6-min walking distance; PAP: pulmonary arterial pressure; CPI: composite physiological index; SGRQ: St George’s Respiratory Questionnaire; TDI: transition dyspnoea index; NA: not applicable. #: only 70 (67%) subjects had baseline pulmonary function data available; ¶: censored at 24 months after enrolment, lung transplant (n=17) was treated as a mortality event.